Serum interleukin-1 beta plays an important role in insulin secretion in type II diabetic

Eizadi Mojtaba*, Kohandel Mahdi, kasbparast JR Mehdi, Sarshin Amir

Department of Physical Education and Sport Science, Karaj Branch, Islamic Azad University, Iran

Received: 12 May 2011
Revised: 26 May 2011
Accepted: 27 May 2011

Key words: Type II diabetes, Interleukin-1 beta, Beta cell function.

Abstract
The proinflammatory cytokine Interleukin-1beta is increased in presence obesity or its related disorders. The objective of this study was to determine serum IL-1β in relation to some markers indicative of type II diabetic. For this purpose, blood samples were collected from brachial vein after a overnight fast between 8:00 and 9:00 a.m. o'clock in order to measuring serum IL-1β, glucose, insulin and beta cell function in a group of type II diabetic men patients (n = 30) and none-diabetic healthy subjects (n = 36) matched for BMI and age in order 1) to compare serum IL-1b between diabetic and none-diabetic subjects, 2) to determine serum IL-1b in relation to fasting glucose, insulin and beta cell function in diabetic patients. All anthropometrical indexes were also measured in two groups. Statistical analysis was performed by Independent sample T-test and Spearman rank correlation method. P value of <0.05 was accepted as significant. Insulin resistance and fasting glucose and serum IL-1b were significantly higher and serum insulin and Beta cell function were significantly lower in diabetic patients than none-diabetic subjects (p < 0.05). Serum IL-1b was negatively correlated with insulin and beta cell function and positively related with fasting glucose in diabetic patients (p < 0.05). Based on this data, it was concluded that IL-1b as a inflammation cytokine play a important role in type II diabetic and insulin secretion of pancreatic beta cell.

*Corresponding Author: Eizadi Mojtaba izadimojtaba2006@yahoo.com
Introduction
Diabetes is known to high insulin concentration and is a metabolic disease that occurs when pancreatic islets fail to produce sufficient insulin and/or the sensitivity of glucose-metabolizing tissues to insulin decreases (Wang et al., 2010). In other words, the pathophysiological hallmarks of type 2 diabetes mellitus are insulin resistance and beta cell dysfunction (Kahn, 2003). It is reported that mechanisms of islet β cell failure are different in the progression of type 1 and type 2 diabetes (Wang et al., 2010). In individuals without diabetic, insulin secretion of beta cells is linked to peripheral insulin sensitivity through a postulated negative feedback loop that allows the beta cells to compensate for any change in whole-body insulin sensitivity by a proportionate and reciprocal change in insulin secretion (Retnakaran et al., 2005). It is generally accepted that insulin resistance is the primary defect and that pancreatic beta cell dysfunction occurs later that contributes to the progression of diabetes. However, a number of studies conducted in Asian populations have demonstrated the dominant role of beta cell dysfunction in the pathogenesis of type 2 diabetes (Kim et al., 2011; Matsumoto et al., 1997).

Beta cells dysfunction is mainly destructed by autoimmune-mediated apoptosis, leading to the loss of insulin production. Inflammatory cytokines play crucial roles in this process (Kawasaki et al., 2004). Chronic exposure of β cell to circulating inflammation cytokines induces excessive production of reactive oxygen species (ROS) and activation of caspases, which inhibit insulin secretion and promote apoptosis of pancreatic β cells (Andersson et al., 2001). The inflammation and anti-inflammation cytokines as leptin, resistin or adiponectin play important role in beta cells dysfunction and type 2 diabetic prevalence (Wang et al., 2010). Depending on their roles in regulating pancreatic β-cell function, some cytokines are protective, others can be detrimental (Wang et al., 2010). Among them, interleukin 1-beta (IL-1β) is a proinflammatory cytokine that plays important roles in inflammation. However, the role of this cytokine under physiological conditions Remains to be clearly delineated. A recent study showed that IL-1β plays an important role in lipid metabolism by regulating insulin levels and lipase activity under physiological conditions (Matsuki et al., 2003). A number of studies have described a positive association between IL-1β gene polymorphism and obesity, suggesting functional effects on fat mass, fat metabolism and body mass (Manica-Cattani et al., 2010). In the past decades, it had been well established that inflammatory cytokines including IL-1β play a critical role in the pathogenesis of type 1 diabetes (Wang et al., 2010), although its role in type 2 diabetic are still not completely elucidated. It is necessary to determine the role of Il-1b in insulin action and its secretion of pancreatic beta cells. Therefore, the main objective of our work was to study the relation of serum IL-1β to fasting glucose, insulin and beta cell function in type II diabetic patients. We also compared above mentioned variables in these patients with healthy subjects.

Material and methods
The aims of present study were 1) to compare the baseline serum IL-1β, glucose, insulin and beta cell function between type II diabetic and those none diabetic men subjects, 2) to determine serum IL-1β in relation to the other above mentioned variables in diabetic patients. The study protocol was approved by the ethics committee of Islamic Azad University. For this purpose, blood samples were collected from brachial vein after a overnight fast between 8:00 and 9:00 a.m. o’clock in order to measuring serum IL-1β, glucose, insulin and beta cell function in a group of type II diabetic men patients (n = 30) and none-diabetic healthy subjects (n = 36) matched for BMI and age (BMI ≥ 30 kg/m2, aged 37 ± 5 years). Each participant received written and verbal explanations about the nature of the study before signing an informed consent form.
Inclusion or Exclusion criteria
Participants were non-athletes, non-smokers and non-alcoholics. Adolescents with other respiratory, cardiac, rheumatic, musculoskeletal and orthopedic diseases and with associated neurological sequelae were excluded from both groups. In addition, the exclusion criteria were infections, renal diseases, hepatic disorders, use of alcohol, and use of nonselective β blockers and presence of malignancy. Neither the control or diabetic subjects had participated in regular exercise/diet for the preceding 6 months, nor did all subjects have stable body weight. Those patients who were unable to avoid taking hypoglycemic drugs or insulin sensitivity-altering drugs for 12 hours before blood sampling were also barred from participating in the study. Subjects were asked to avoid doing any heavy physical activity for 48 hours before blood sampling.

Anthropometric measurements
Weight and height of the participants were measured by the same person when the participant had thin clothes on and was wearing no shoes by using the standard scales. Body mass index was measured for each individual by division of body weight (kg) by height (m2). Also, Waist to hip circumference ratio (WHO) was calculated through dividing the abdominal circumference by hip circumference. Visceral fat and body fat percentage was determined using body composition monitor (OMRON, Finland).

Assay
Glucose was determined by the oxidase method (Pars Azmoon kit, Tehran). Serum IL-1β was determined by ELISA method (Enzyme-linked Immunosorbent Assay for quantitative detection of human IL-1β), using a Biovendor- Laboratorial kit made by Biovendor Company, Czech. The Intra-assay coefficient of variation and sensitivity of the method were 5.1% and 0.3 pg/mL, respectively. Insulin was determined by ELISA method (Demeditec, Germany) and the intra-assay and inter-assay coefficient of variation of the method were 2.6% and 2.88 respectively. Beta cell function (HOMA-BF) = [(20 × fasting insulin (μ/ml) / [Fasting glucose (mmol/l) – 3.5)] (Greenman et al., 2004).

Statistical analysis: All values are represented as mean ± SD. Statistical analysis was performed with the SPSS software version 15.0. The Kolmogorov-Smirnov test was applied to determine the variables with normal distribution. An Independent sample T-test was used to compare the serum levels of all variables between obese and none-obese subjects. The bivariate associations between IL-1β concentration with glucose, insulin and beta-cell function were examined with the Spearman rank correlation analysis in obese subjects. A p-value less than 0.05 were considered statistically significant.

Results
Data were expressed as individual values or the mean ± SD. Baseline characteristics such as age, body weight, BMI and body fat percentage did not differ between two groups (p ≥ 0.05). These data showed that fasting glucose concentration (101 ± 12 vs. 225 ± 35 mg/dl, p=0.000) and insulin resistance index (2.10 ± 0.33 vs. 4.58 ± 0.98, p=0.031) were higher in diabetic patients than none-diabetic. The finding of independent sample T-test were also showed lower serum insulin in diabetic patients than those with none diabetic (8.41 ± 2.11 vs. 711 ± 2.11 mg/dl, p = 0.021). Additionally, serum IL-1β concentrations were significantly higher in the type 2 diabetics than in the none-diabetic group (2.01 ± 0.21 vs. 2.81 ± 0.31 ng/ml, p = 0.012). Also, beta cell function in studied patients was lower than none-diabetic subjects (85.66 ± 21.3 vs 22.14 ± 6.11, p=0.000). Statistical analysis by Pearson method showed Baseline serum IL-1β was not correlated with insulin resistance in diabetic patients, while this inflammation cytokine was significantly negative associated with beta cell function (p = 0.016, r = 0.40, Fig 1). These finding support the role of IL-1β in beta cell dysfunction.
In addition, a significant positive association was observed between fasting glucose concentration with serum IL-1b in studied patients (p = 0.000, r = 0.62). This study has also shown a negatively association between IL-1b and insulin concentration in studied patients. (p = 0.0083, r = 0.44, Fig 2). Serum IL-1b was found to be positively associated with visceral fat in patients (p = 0.004, r = 0.47).

**Discussion**

Our study finding showed higher fasting glucose and insulin resistance in diabetic patients compared to none-diabetic subjects, while serum insulin and beta cell function in these patients were significantly lower than those without diabetes. These finding have been reported repeatedly by previous studies (Maedler et al., 2009). In present study, we also observed that Serum IL-1β concentrations were significantly higher in the type 2 diabetics than in the healthy subjects. Proinflammatory cytokines secreted by adipose tissue and the other tissues can cause insulin dysfunction in adipose tissue, skeletal muscle and liver by inhibiting insulin signal transduction. Accumulating evidence indicates that the diseases related to metabolic syndrome are characterized by abnormal cytokine production, including elevated circulating IL-1β, increased acute-phase proteins, e.g., CRP (Sauter et al., 2008) and activation of inflammatory signaling pathways (Juge-Aubry et al., 2003). Recent evidence has shown that IL-1β plays a role in various diseases, including autoimmune diseases such as inflammatory bowel diseases and type 1 diabetes, rheumatoid arthritis, as well as in diseases associated with metabolic syndrome such as atherosclerosis, chronic heart failure and type 2 diabetes (Maedler et al., 2009). Macrophage is known as the primary source of IL-1, but epidermal, epithelial, lymphoid and vascular tissues also synthesize IL-1. IL-1β production and secretion have also been reported from pancreatic islets (Maedler et al., 2009).

The major finding of this investigation was negative significant association between serum IL-1β with beta cell function. To support our data, it is reported that increased secretion of IL-1β have been linked not only to various autoimmune and auto-inflammatory diseases, but also to metabolic dysregulation (Dinarello, 2009) and a disturbance in its secretion is associated with type II diabetic and impaired beta cell function (Mandrup-Poulsen et al., 1998; Eizirik, 1998). A number of studies have demonstrated that
low concentration of IL-1β stimulates insulin release and proliferation in rat and human islets (Maedler et al., 2006; Schumann et al., 2007). A recent study states that increased IL-1β levels is accompanied with impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells (Osborn et al., 2008). Rather than being directly cytotoxic, IL-1β may drive tissue inflammation that impacts on both beta cell functional mass and insulin sensitivity in type 2 diabetes (Ehses et al., 2009). In addition to impaired insulin secretion, IL-1β was found to induce β-cell death, which was potentiated by TNF-α (Eizirik, 1998). It was found that blocking IL-1β by IL-1β -neutralizing antibodies conferred protection from the cytotoxic effects induced by activated-mononuclear-cell-conditioned medium and this data demonstrated that IL-1β plays an important role in the molecular mechanisms underlying autoimmune β-cell destruction (Bendtzen et al., 1986). Several studies have found an overexpression of MnSOD also protects IL-1β cells from IL-1β or other cytokine induced apoptosis by repressing NF-κB activation and iNOS expression (Azevedo-Martins et al., 2003).

In present study, serum IL-1β also correlated negatively with the serum insulin and positively with glucose concentration in diabetic patients that support the role of insulin secretion of pancreatic beta cells. This proinflammatory cytokine also is known to induce vascular dysfunction and cell death and its inhibition might represent a new strategy to inhibit capillary degeneration in diabetic retinopathy (Vincent et al., 2007). There is evidence that short-time pretreatment of pancreatic β cells with IL-1β, IFN-γ, and TNF-α, alone or in combination, results in significant inhibition of insulin secretion in the absence or presence of stimulatory glucose concentration (Zhang et al., 1995; Kiely et al., 2007). Chronic exposure of IL-1β cell of pancreas to IL-1β activates the expression of inducible nitric oxide synthase and results in excessive production of nitric oxide (NO), which interferes with electron transfer, inhibits ATP synthesis in mitochondria, and induces the expression of proinflammatory genes (Yang et al., 2010). It is reported that a decrease in cellular ATP content inhibits insulin secretion and results in cell dysfunction (Wang et al., 2010). In a recent study, administration of IL-1β-neutralizing antibody for 13 weeks significantly reduces glycated hemoglobin (0.45%) and improves islet function in HFD-induced diabetic mice (Osborn et al., 2008). It has been demonstrated that pioglitazone also protects human islet IL-1β cells from IL-1β-induced apoptosis by blocking NF-κB activation (Suk et al., 2001). One study reported that the expression of islet-derived proinflammatory cytokines including IL-1β and TNF-α is reduced by IL-1ra treatment with amelioration of islet inflammation (Ehses et al., 2009).

Altogether, this study has two important findings: the first one is that the levels of IL-1β as an inflammatory cytokines in patients with diabetes are far higher than those with non-diabetic counterparts. Secondly the serum levels of this inflammatory cytokine are significantly correlated with beta cell function. Thus the inverse relationship between serum levels of IL-1β and beta cell function somehow supports the role of increased IL-1β in pancreatic beta-cell dysfunction and further corroborates the hypothesis that increased secretion of this cytokine reduces the amount of secretion of insulin from beta cells; because in the present study a significant inverse relationship was observed between levels of IL-1β and insulin and showed that each subject, increased serum levels of IL-1β were associated with decreased insulin concentration. On the other hand, the positive and significant relationship between IL-1β and blood glucose concentration in diabetic patients was another finding of this study which supports the role of this inflammatory cytokine in prevalence of diabetes and the determining parameters of type II diabetes. Finally, although like some previous studies, the findings of this study support the role of IL-1β in...
pathophysiology of type II diabetes and beta cell function, the main mechanisms of interaction between them are still unknown and call for further studies in this field.

References


Juge-Aubry CE, Somm E, Giusti V. 2003. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52, 1104-10.


Maedler K, Schumann DM, Sauter N. 2006. Low concentration of interleukin-1 β induces FLICE-


